<DOC>
	<DOCNO>NCT00753896</DOCNO>
	<brief_summary>This study examine safety exenatide weekly ( 2.0 mg ) approximately 134 patient receive treatment thiazolidinedione alone thiazolidinedione combination metformin . Patients expect treated exenatide weekly least 52 week .</brief_summary>
	<brief_title>Safety Exenatide Once Weekly Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone Thiazolidinedione Combination With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Have type 2 diabetes At least 18 year age screening . Have HbA1c 7.1 % 10.0 % , inclusive , screen . Have body mass index ( BMI ) 25 kg/m2 45 kg/m2 , inclusive . Have treat stable dose TZD ( ≥4 mg/day rosiglitazone ≥30 mg/day pioglitazone ) least 120 day prior Visit 1 OR Have treat stable dose TZD ( ≥4 mg/day rosiglitazone ≥30 mg/day pioglitazone ) least 120 day PLUS stable dose metformin least 90 day prior Visit 1 . Have history stable body weight ( vary &gt; 10 % least 3 month prior screen ) . If female childbearing potential ( surgically sterilize menarche 1year postmenopause ) . Are breastfeed . Test negative pregnancy time screen base serum pregnancy test . Intend become pregnant study . Have practice reliable method birth control ( e.g. , use oral contraceptive approve hormonal implant ; diaphragm contraceptive jelly ; cervical cap contraceptive jelly ; condom contraceptive foam ; intrauterine device ; partner vasectomy ; abstinence ) least 6 week prior screen . Agree continue use reliable method birth control ( see ) study . Have clinically significant history cardiac disease presence active cardiac disease within year prior inclusion study , include myocardial infarction , clinically significant arrhythmia , unstable angina , coronary artery bypass surgery , angioplasty . Is expect require coronary artery bypass surgery angioplasty course study . Have obvious clinical sign symptom liver disease , acute chronic hepatitis Have history renal transplantation currently receive renal dialysis serum creatinine ≥135 μmol/L male ≥110 μmol/L female . Have active untreated malignancy , remission clinically significant malignancy ( basal cell squamous cell skin cancer , situ carcinoma cervix , situ prostate cancer ) less 5 year . Have know hemoglobinopathy chronic anemia ( hemoglobin concentration &lt; 11.5 g/dL [ 115 g/L ] male , &lt; 10.5 g/dL [ 105 g/L ] female ) . Have clinically significant history presence severe gastrointestinal disease , particularly may impact gastric emptying , gastroparesis , pyloric stenosis , gastric bypass surgery . Have history pancreatitis . Have great three episode major hypoglycemia within 6 month prior screen . Have contraindication OAD ( ) use , accord local label requirement . Are know active proliferative retinopathy . Are receive chronic ( &gt; 2 week ) systemic glucocorticoid therapy ( exclude topical inhale preparation ) receive systemic glucocorticoid therapy &gt; 2 week within 4 week immediately precede screen . Have treat drug promote weight loss ( e.g. , Xenical® [ orlistat ] , Meridia® [ sibutramine ] , Acomplia® [ rimonabant ] , Acutrim® [ phenylpropanolamine ] , similar overthecounter medication ) within 3 month screen . Have previously treat glucagonlike peptide 1 analog liraglutide . Have treat longer 2 week follow excluded medication within 3 month prior screen : Insulin ; Sulfonylureas ; Alphaglucosidase inhibitor ( e.g. , Glyset® [ miglitol ] Precose® [ acarbose ] ) ; Meglitinides ( e.g. , Prandin® [ repaglinide ] Starlix® [ nateglinide ] ) ; Dipeptidyl peptidase ( DPP ) 4 inhibitor ( e.g. , Januvia™ [ sitagliptin ] , Galvus® [ vildagliptin ] ) ; Symlin® ( pramlintide acetate ) . Have organ transplant . Have donate blood within 30 day screen . Have previously complete withdrawn study study investigate exenatide weekly . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Are currently participate interventional medical , surgical , pharmaceutical study ( study experimental , drug , medical , surgical treatment give ) . Patients complete final visit study examine safety/efficacy exenatide BID may enter study day meet eligibility criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
	<keyword>exenatide weekly</keyword>
	<keyword>thiazolidinedione</keyword>
	<keyword>metformin</keyword>
</DOC>